查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961133

药物递送市场－全球产业规模、份额、趋势、机会、预测：依给药途径、应用、区域和竞争格局划分，2021-2031年

Pharmaceutical Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球药物输送市场预计将从 2025 年的 21.2 亿美元成长到 2031 年的 29.7 亿美元，复合年增长率为 5.76%。

该领域的特点是采用专门的系统和製剂，旨在将治疗药物输送到特定的生理部位，从而确保最大的医疗疗效。市场成长的主要驱动力是全球慢性病盛行率的上升以及生物製药领域的快速发展，后者需要超越传统口服给药方式的精准给药技术。欧洲製药工业协会联合会 (EFPIA) 估计，到 2024 年，欧洲以研发为基础的製药业的研发投资将达到 550 亿欧元，这充分体现了推动这些先进技术发展的雄厚资金实力。

市场概览
预测期 2027-2031
市场规模：2025年 21.2亿美元
市场规模：2031年 29.7亿美元
复合年增长率：2026-2031年 5.76%
成长最快的细分市场 局部给药
最大的市场 北美洲

然而，由于法规结构对新型递送系统和复合产品有着严格的限制，市场面临许多障碍。例如，基于奈米技术的载体等先进系统的核准流程十分复杂，通常需要大量的临床检验，且耗费巨额研发成本。这些监管要求提高了市场准入门槛，并可能显着延缓商业化进程，阻碍创新递送解决方案快速进入全球市场。

市场驱动因素

慢性病和非传染性疾病的日益增多是全球药物递送市场的主要驱动力，因此标靶和缓释机制的引入势在必行。在肿瘤学领域，抗体药物复合体（ADC）和奈米颗粒载体的需求不断增长，以提高治疗指数。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》，美国新增癌症病例数预计将首次超过200万，凸显了精准递送系统的重要性。这种流行病学变化促使製造商专注于开发能够确保长期用药依从性和疗效的製剂和装置。

同时，为支援复杂药物製剂和生命週期管理（尤其是不断扩大的生物製药研发管线）而增加的研发投入，正在推动这一领域的发展。製药公司正大力投资，透过创新的给药方式来解决大分子药物的稳定性和生物利用度难题。根据2024年9月发布的《2024年美国药品研究与製造商协会年度会员调查》，会员公司在2023年的研发投入达到了创纪录的1031亿美元，这一资金投入正在加速先进技术的商业化进程。此外，美国食品药物管理局（FDA）在2024年宣布，其药物评估与研究中心上年度核准了55种新疗法，显示需要特殊给药方式的产品种类显着增加。

市场挑战

围绕新型药物递送系统的严格监管环境是限制全球药物递送市场成长的主要阻碍因素。监管机构对复杂产品和先进载体实施严格的标准，要求製造商进行广泛而漫长的临床试验以证明其安全性和有效性。这种复杂的核准流程显着延长了研发週期，并延缓了新型药物递送系统的商业化。因此，企业面临长期的不确定性和投资回报延迟，阻碍了高风险创新计划的开展，并限制了新产品的上市数量。

这些监理障碍直接转化为沉重的财务负担，构成高进入门槛，阻碍市场扩张。对全面检验数据的需求迫使製造商将大量资源投入研发阶段，这往往使小规模企业在财务上举步维艰。根据美国製药製造商协会（PhRMA）预测，其成员公司在2024年的研发支出预计将达到创纪录的1035亿美元，反映出应对这一高要求研发路径所带来的成本飙升。这种巨大的财务压力限制了市场参与者快速推出多样化解决方案的能力，最终减缓了整个产业的整体发展进程。

市场趋势

穿戴式输液设备在慢性病治疗领域的普及，从根本上改变了给药环境，使患者能够在临床环境之外管理复杂的治疗方案。与传统的肠外给药方式不同，这些隐藏的无管系统能够持续皮下输注大剂量生物製药，直接满足了患者对生活方式导向治疗方案的需求。这种转变在糖尿病管理领域尤其明显，自动给药系统的需求正在激增。根据Insullet公司于2024年11月发布的2024年第三季财报，其季度销售额达到5.439亿美元，年增25.7%。这主要归功于该公司OmniPod 5自动胰岛素给药系统的快速普及，显示整个产业正在向将药物储存和给药功能整合到单一、便于患者使用的单元中的设备转变。

采用互联智慧设备监测用药依从性，标誌着数位医疗和药物传输技术的显着整合。製造商正越来越多地将蓝牙和感测器技术等连接功能整合到其药物传输系统中，以即时收集给药数据，为医疗专业人员提供可操作的洞察，并提高患者的用药依从性。这种整合建构了闭合迴路生态系统，使药物传输设备能够直接与行动应用程式通信，实现剂量追踪和演算法调整的自动化。根据Ipsomed Holding AG于2024年11月发布的《2024/25财政年度半年报》，其mylife Loop解决方案（将胰岛素帮浦与基于智慧型手机的演算法连接）截至2024年9月底已拥有约6万用户。这显示市场正从简单的机械工具发展到能够优化治疗效果的智慧数据生成平台。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球药物输送市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 给药途径（口服给药、鼻腔给药、眼部给药、局部给药、其他）
    • 依应用领域（癌症、感染疾病、糖尿病、心血管疾病等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美药物输送市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲药物输送市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区药物传输市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲药物输送市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲药物输送市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球药物输送市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Johnson & Johnson
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Bayer AG
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen, Inc.
  • AbbVie Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23145

The Global Pharmaceutical Drug Delivery Market is projected to expand from a valuation of USD 2.12 Billion in 2025 to USD 2.97 Billion by 2031, reflecting a CAGR of 5.76%. This sector is defined by specialized systems and formulations designed to transport therapeutic agents to targeted physiological sites, thereby ensuring maximum medical efficacy. The market is primarily underpinned by the increasing global incidence of chronic diseases and the burgeoning biologics sector, which demands precise administration techniques beyond conventional oral routes. Illustrating the significant capital driving these advanced technologies, the European Federation of Pharmaceutical Industries and Associations estimated in 2024 that the research-based pharmaceutical industry invested €55,000 million in R&D across Europe.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.12 Billion
Market Size 2031USD 2.97 Billion
CAGR 2026-20315.76%
Fastest Growing SegmentTopical Drug Delivery
Largest MarketNorth America

However, the market faces considerable obstacles due to the rigorous regulatory framework governing new delivery vehicles and combination products. The approval process for advanced systems, such as nanotechnology-based carriers, is intricate, often requiring extensive clinical validation and incurring exorbitant development costs. These regulatory demands create high barriers to entry and can significantly postpone commercialization, potentially hindering the rapid introduction of innovative delivery solutions to the global landscape.

Market Driver

The escalating burden of chronic and non-communicable diseases acts as a major catalyst for the global drug delivery market, necessitating the deployment of targeted and sustained-release mechanisms. In the field of oncology, there is an intensifying demand for antibody-drug conjugates and nanoparticle carriers to enhance therapeutic indices. According to the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, new cancer diagnoses in the United States are projected to exceed 2 million for the first time, underscoring the critical need for precision delivery systems. This epidemiological shift compels manufacturers to focus on developing formulations and devices that ensure medication adherence and efficacy for long-term management.

Simultaneously, the sector is being propelled by increased R&D investments in complex drug formulation and lifecycle management, particularly to support the expanding biologics pipeline. Pharmaceutical companies are allocating substantial capital to resolve stability and bioavailability challenges associated with large-molecule therapeutics through innovative delivery vehicles. As per the '2024 PhRMA Annual Membership Survey' published in September 2024, member companies reported a record-high $103.1 billion investment in research and development during 2023, a financial commitment that accelerates the commercialization of advanced technologies. Furthermore, the U.S. Food and Drug Administration noted in 2024 that the Center for Drug Evaluation and Research approved 55 novel therapeutics in the preceding year, significantly broadening the landscape of products requiring specialized administration.

Market Challenge

The stringent regulatory landscape regarding novel delivery vehicles constitutes a primary restraint on the growth of the global pharmaceutical drug delivery market. Regulatory bodies enforce rigorous standards for combination products and advanced carriers, requiring manufacturers to conduct extensive and prolonged clinical trials to demonstrate safety and efficacy. This complex approval process extends development timelines significantly, delaying the commercial availability of new delivery systems. Consequently, companies face prolonged periods of uncertainty and delayed return on investment, which discourages the pursuit of high-risk innovative projects and limits the volume of new products entering the market.

These regulatory hurdles directly translate into substantial financial burdens, creating a high barrier to entry that hampers market expansion. The necessity for comprehensive validation data forces manufacturers to allocate immense resources to the research phase, often making development financially unviable for smaller entities. According to the Pharmaceutical Research and Manufacturers of America, in 2024, member companies reported a record research and development expenditure of $103.5 billion, reflecting the escalating costs associated with navigating these demanding development pathways. This intense financial pressure restricts the ability of market players to introduce diverse solutions rapidly, thereby slowing the overall trajectory of the sector.

Market Trends

The proliferation of wearable on-body injectors for chronic conditions is fundamentally reshaping the administration landscape by enabling patients to manage complex therapies outside clinical settings. Unlike traditional parenteral methods, these discreet, tubeless systems offer continuous subcutaneous delivery of large-volume biologics, directly addressing the need for lifestyle-compatible treatment options. This shift is particularly evident in the diabetes management sector, where the demand for automated delivery systems is surging. According to Insulet Corporation's 'Third Quarter 2024 Financial Results' from November 2024, the company reported quarterly revenue of $543.9 million, a 25.7% increase year-over-year, driven largely by the rapid adoption of its Omnipod 5 automated insulin delivery system, indicating a broader industry move toward devices that combine medication storage and propulsion into a single, patient-friendly unit.

The adoption of connected smart devices for adherence monitoring represents a pivotal convergence of digital health and medication delivery technologies. Manufacturers are increasingly embedding connectivity features such as Bluetooth and sensor technology into delivery systems to capture real-time dosing data, thereby enhancing patient compliance and providing actionable insights for healthcare providers. This integration allows for the creation of closed-loop ecosystems where administration devices communicate directly with mobile applications to automate dosage tracking and algorithmic adjustments. According to Ypsomed Holding AG's 'Semiannual Report 2024/25' released in November 2024, the company's mylife Loop solution, which connects an insulin pump to a smartphone-based algorithm, reached approximately 60,000 users by the end of September 2024, underscoring the market's evolution from simple mechanical tools to intelligent data-generating platforms that optimize therapeutic outcomes.

Key Market Players

  • Johnson & Johnson
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Bayer AG
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen, Inc.
  • AbbVie Inc.

Report Scope

In this report, the Global Pharmaceutical Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Drug Delivery Market, By Route of Administration

  • Oral drug delivery
  • Nasal drug delivery
  • Ocular drug delivery
  • Topical drug delivery
  • Others

Pharmaceutical Drug Delivery Market, By Application

  • Cancer
  • Infectious Diseases
  • Diabetes
  • Cardiovascular Diseases
  • Others

Pharmaceutical Drug Delivery Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Drug Delivery Market.

Available Customizations:

Global Pharmaceutical Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Drug Delivery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral drug delivery, Nasal drug delivery, Ocular drug delivery, Topical drug delivery, Others)
    • 5.2.2. By Application (Cancer, Infectious Diseases, Diabetes, Cardiovascular Diseases, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Drug Delivery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Drug Delivery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Pharmaceutical Drug Delivery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Pharmaceutical Drug Delivery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Application

7. Europe Pharmaceutical Drug Delivery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Drug Delivery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Application
    • 7.3.2. France Pharmaceutical Drug Delivery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Pharmaceutical Drug Delivery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Pharmaceutical Drug Delivery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Pharmaceutical Drug Delivery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Application

8. Asia Pacific Pharmaceutical Drug Delivery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Drug Delivery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Application
    • 8.3.2. India Pharmaceutical Drug Delivery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Pharmaceutical Drug Delivery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Pharmaceutical Drug Delivery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Pharmaceutical Drug Delivery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Application

9. Middle East & Africa Pharmaceutical Drug Delivery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Drug Delivery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Pharmaceutical Drug Delivery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Pharmaceutical Drug Delivery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Application

10. South America Pharmaceutical Drug Delivery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Drug Delivery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Pharmaceutical Drug Delivery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Pharmaceutical Drug Delivery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis International AG
  • 15.3. F. Hoffmann-La Roche AG
  • 15.4. Pfizer Inc.
  • 15.5. Bayer AG
  • 15.6. Antares Pharma, Inc.
  • 15.7. Becton, Dickinson and Company
  • 15.8. GlaxoSmithKline plc
  • 15.9. Merck & Co., Inc.
  • 15.10. Amgen, Inc.
  • 15.11. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer